ION Breast Cancer Clinical Pathways - ION Solutions

Gemzar (Gemcitabine) Taxotere (Docetaxel) EP=Low; FN=10%-20%Gemcitabine 1100mg/m 2 D1, D8Docetaxel 100mg/m 2 D8q 21 Day Cycle>> Lancet 357:1478-1484, 2001Clinical Trial:Screen patient for clinical trial. Check www.clinicaltrials.gov for available trials.Best Supportive Care and/or Hospice:Consider supportive care options and Hospice when appropriate.Note: Continuation of Bevacizumab, Pemetrexed or Gemcitabine beyond 4-6cycles and in the absence of disease progression is considered continuationmaintenance therapy.Note: Platinol (Cisplatin) is an appropriate substitution for Paraplatin(Carboplatin) in select patients.Note: For patient to receive Bevacizumab they must NOT have any of thefollowing: squamous cell carcinoma; clinically significant hemoptysis; receivinganticoagulants.Note: Drugs approved for second line metastatic disease for patients withcomorbidities precluding combination treatment.Note: Bevacizumab used with any appropriate combination is consideredcompliant.Non-Small Cell Lung (NSCL): Switch Maintenance TherapyMaintenance Therapy:Alimta (Pemetrexed) EP=Low; FN> Lancet 374:1432-40, 2009Tarceva (Erlotinib)Erlotinib 150mg PO q D>> Lancet Oncol 11:521, 2010Clinical Trial:Screen patient for clinical trial. Check www.clinicaltrials.gov for available trials.Page 27 of 39© 2013 by ION Solutions. All rights reserved